Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC19H22N6O5S |
InChIKeyFAZNWIGAOYXZGW-UHFFFAOYSA-N |
CAS Registry1105110-83-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 01 Nov 2022 |